Pharmaceutical LSD reports one of the largest antidepressant effect sizes on record
A Phase 3 trial of a pharmaceutical LSD formulation for major depression reported a large, rapid, and durable reduction in symptoms, meeting its primary and secondary endpoints — among the strongest effect sizes reported for any antidepressant in a controlled trial. Independent, non-industry replication and peer-reviewed publication are the next tests.
Reported June 2026 · late-stage clinical trial data · reliability: strong signal, awaiting full peer review.
A 2026 meta-analysis finds a standard psilocybin dose clearly beats control for depression
Pooling six randomized controlled trials, a meta-analysis found a standard (25 mg) psilocybin dose superior to control for major depression — with higher response and remission rates sustained for weeks, and lower dropout than control. A low dose showed no such advantage. It's some of the firmest evidence yet that dose and context matter.
Kishi et al., Journal of Affective Disorders, 2026 · meta-analysis of 6 RCTs · reliability: strong (peer-reviewed).
U.S. regulators grant their first priority reviews for psychedelic therapies
In 2026 the FDA issued national priority vouchers to several psychedelic programs — including psilocybin for depression and an MDMA-analog for PTSD — a mechanism that can compress review timelines substantially. It's a signal of how quickly the regulatory landscape is shifting, even as these substances remain federally controlled.
Reported 2026 · regulatory action · reliability: strong (official).
Antidepressant effect of a single psilocybin course appears to last up to a year
A 12-month follow-up from a European trial reported that the antidepressant effect of psilocybin, given alongside psychological support, was still measurable a year later. Long-term, real-world durability across larger and more diverse groups remains an open question.
EPIsoDE follow-up, Psychotherapy and Psychosomatics, 2026 · reliability: moderate–strong (peer-reviewed, single trial).
The honest caveat we attach to all of it
Most of this research asks whether psychedelics can treat illness. Metanoia's question is different — whether, used carefully, they can help healthy people thrive — and there the evidence is genuinely promising but far less settled. We report the field as it is: the strong results and the thin ones, side by side. None of this is medical or legal advice, and these substances remain controlled in most places.